Page last updated: 2024-10-31

nabumetone and Peptic Ulcer

nabumetone has been researched along with Peptic Ulcer in 14 studies

Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.

Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).

Research Excerpts

ExcerptRelevanceReference
", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee."9.09Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999)
"The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs."9.09Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000)
"To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)."9.09[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001)
" Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others."8.78Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992)
"To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen."7.73Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005)
", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee."5.09Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999)
"The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs."5.09Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000)
"To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial."5.09Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001)
"To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)."5.09[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001)
"The objective of this endoscopic, double-blind study was to evaluate the gastric tolerability of nabumetone, a novel nonsteroidal anti-inflammatory drug, compared with naproxen in patients with rheumatoid arthritis."5.08Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Petrillo, M, 1995)
"To compare the gastrointestinal safety, ulcerogenic potential, and clinical efficacy over 5 years of nabumetone and naproxen therapy, in patients with rheumatoid arthritis (RA) or osteoarthritis (OA)."5.07A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. ( Bennett, R; Caldron, P; Koepp, R; Mitchell, C; Roth, SH; Swenson, C, 1994)
" In an ongoing study of patients with osteo- or rheumatoid arthritis, currently in its fourth year, nabumetone has been shown to be relatively gastric sparing when compared with naproxen."5.06New understandings of NSAID gastropathy. ( Roth, SH, 1989)
"A total of 1,924 persons (rheumatoid arthritis, 835; osteoarthritis, 1,073; volunteers, 16) received nabumetone in United States clinical trials."5.06Safety evaluation of nabumetone in United States clinical trials. ( Brindley, DA; Jackson, RE; Mitchell, FN, 1987)
"Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo."4.80Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999)
" Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others."4.78Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992)
"To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen."3.73Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19902 (14.29)18.7374
1990's8 (57.14)18.2507
2000's4 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ashworth, NL1
Peloso, PM1
Muhajarine, N1
Stang, M1
Bianchi Porro, G1
Montrone, F1
Petrillo, M1
Caruso, I1
Imbesi, V1
Roth, SH5
Bennett, R1
Caldron, P1
Mitchell, C1
Swenson, C1
Koepp, R1
Tindall, EA1
Jain, AK1
McMahon, FG1
April, PA1
Bockow, BI1
Cohen, SB1
Fleischmann, RM1
Lanza, FL1
Agrawal, NM1
Caldwell, J1
Kivitz, AJ1
Weaver, AL1
Bocanegra, TS1
Ball, J1
Dhadda, S1
Hurley, S1
Hancock, L1
Langman, MJ1
Jensen, DM1
Watson, DJ1
Harper, SE1
Zhao, PL1
Quan, H1
Bolognese, JA1
Simon, TJ1
Scott, DL1
Palmer, RH1
Morgan , GJ1
Kaine, J1
DeLapp, R1
Palmer, R1
Jackson, RE1
Mitchell, FN1
Brindley, DA1

Reviews

4 reviews available for nabumetone and Peptic Ulcer

ArticleYear
Gastrointestinal toxicity of newer NSAIDs.
    The American journal of gastroenterology, 1993, Volume: 88, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; N

1993
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    JAMA, 1999, Nov-24, Volume: 282, Issue:20

    Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg

1999
Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis.
    Orthopaedic review, 1992, Volume: 21, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Humans; Nabumetone; Osteo

1992
NSAID gastropathy. The central issue.
    Drugs, 1990, Volume: 40 Suppl 5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Naproxen; Peptic Ulcer

1990

Trials

9 trials available for nabumetone and Peptic Ulcer

ArticleYear
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
    The American journal of gastroenterology, 1995, Volume: 90, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method; Duod

1995
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.
    The Journal of rheumatology, 1994, Volume: 21, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method

1994
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
    Archives of internal medicine, 1993, Nov-22, Volume: 153, Issue:22

    Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endoscopy, Digestive

1993
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
    Clinical therapeutics, 1999, Volume: 21, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr

1999
Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Digestive System; Double-Blind Meth

2000
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
    Journal of clinical gastroenterology, 2001, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D

2001
[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis].
    Zhonghua yi xue za zhi, 2001, May-10, Volume: 81, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones;

2001
New understandings of NSAID gastropathy.
    Scandinavian journal of rheumatology. Supplement, 1989, Volume: 78

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Clinical Trials as Topic

1989
Safety evaluation of nabumetone in United States clinical trials.
    The American journal of medicine, 1987, Oct-30, Volume: 83, Issue:4B

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Tri

1987

Other Studies

1 other study available for nabumetone and Peptic Ulcer

ArticleYear
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
    The Journal of rheumatology, 2005, Volume: 32, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas

2005